Preliminary study on the efficacy and safety of atorvastatin in northern Han patients with acute ischemic cerebrovascular disease
10.11855/j.issn.0577-7402.2015.07.02
- Author:
Xue-Dan ZHENG
1
Author Information
1. Department of Neurology, General Hospital of Shenyang Command
- Publication Type:Journal Article
- Keywords:
Atorvastatin;
Stroke;
Validation studies
- From:
Medical Journal of Chinese People's Liberation Army
2015;40(7):519-525
- CountryChina
- Language:Chinese
-
Abstract:
Objective Depending on the stratification of risk factors, to observe the efficacy and safety of different doses of atorvastatin in patients of northern Han population with acute ischemic cerebrovascular disease. Methods One hundred and sixty patients with acute ischemic cerebrovascular disease, admitted from Oct. 2013 to Jan. 2014, were involved in present study, and they were divided into three groups according to the etiology and pathogenesis. In addition to routine treatment, three groups of patients were given 20mg (n=50), 40mg (n=50) and 60mg (n=60) atorvastatin, respectively. Lipids contents, liver function, renal function, muscle enzymes, high sensitivity C reactive protein (hCRP) levels, and NIH Stroke scale (NIHSS) score were determined respectively before treatment and before discharge from the hospital. Results Blood lipid levels were reduced in all the 3 groups, total cholesterol (TC), high density lipoprotein cholesterol-C (HDL-C) and low density lipoprotein cholesterol-C (LDL-C) lowered obviously with significant difference among the 3 groups (P<0.05); while the triglyceride (TG) level showed less lowering, and no statistical difference was found among groups (P>0.05). The highest compliance rate of LDL-C was observed in 60mg group. Compared with those before treatment, the mean levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were elevated, and that of total bilirubin (TBil) and direct bilirubin (DBil) declined after treatment (P<0.05). The levels of blood urea nitrogen (BUN) and creatinine (Cr) were lowered, while that of glomerular filtration rate (GFR) increased compared with those before treatment, but there was no significant difference among groups (P>0.05). The average level of creatine kinase (CK) was lowered (P<0.05), while that of creatine kinase-MB (CK-MB) became higher (P<0.01) after treatment as compared with that before treatment. After treatment, the level of hypersensitive C-reactive protein (hCRP) declined in 20mg and 40mg group, and increased in 60mg group, but the changes showed no significant difference among the 3 groups (P>0.05). NIHSS scores were decreased in a dose-dependent manner after treatment with no significant difference among the 3 groups (P=0.157). Conclusions Atorvastatin can safely and effectively reduce the blood lipid levels, improve the neurological deficits, and reduce the hCRP level to certain extent. Administration of 60mg of atorvastatin may result in highest compliance rate of LDL-C and the greatest degree of improvement of NIHSS. However, further study should be untaken to demonstrate if the long-term and high-dose medication of atorvastatin is safe and effective for ischemic stroke.
